Alembic Pharma Posts Q4 Net Of Rs 35 Cr As India And US Businesses Grow

Published date: .

Alembic Pharmaceutical Ltd. (APL) posted a net profit of Rs 35 crore for the quarter ending March 31, 2022 after charging off non-recurring expenses of Rs. 188 crore, gaining from growth in its India and US businesses.

The company's India branded business was up by 25 per cent year-on-year (YoY) in Q4 of FY'22 at Rs 449 crore, up from Rs 358 crore in Q4 of previous fiscal year. APL's US generics business also grew by 17 per cent to Rs 557 crore in Q4 of FY'22 as against Rs 475 crore in Q4 of FY'21.

During the quarter, Alembic Pharma's US portfolio strengthened with the acquisition of the balance 40 per cent stake in Aleor Dermaceuticals, making it a wholly owned subsidiary of the company, managing director Pranav Amin stated.

Shaunak Amin, managing director of Limited, said the Indian business grew across most of products and therapy areas.

However, APL's overseas formulations business excluding the US fell by 29 per cent to Rs 188 crore in Q4 of FY'22 as against Rs 233 crore in Q4 of FY'21. On the other hand, its active pharmaceutical ingredients (API) grew only marginally by four per cent to stand at Rs 222 crore in the quarter.

In its international generics business, the company filed 23 abbreviated new drug applications (ANDAs) in FY'22 even as 23 ANDA approvals were received, taking cumulative ANDA filings to 230 and approvals to 160, respectively. During the fourth quarter, APL also filed three drug master files (DMFs) in its API business.

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor